DNA methylation may influence the effects of aspirin in patients with breast cancer
Women with a particular DNA feature may live longer if they take aspirin even before they are diagnosed with breast cancer, a new study found.
A team of researchers at the University of North Carolina hypothesized that epigenetic changes might help shed light on the underlying biologic mechanism that links aspirin use to breast cancer outcomes.
Published in the journal, Cancer, the study could help create new preventive measures against breast cancer, like taking aspirin to prevent or treat breast cancer in some people.
Until today, it’s still uncertain why some people with breast cancer respond to a specific therapy while others don’t. An unending question in clinical and population health research is about the human response to treatments, and why it varies in this study, which was acquired from collective findings from the Long Island Breast Cancer Study Project.
In some instances, gene sequences may play a pivotal role, but in some cases, DNA chemical modifications or epigenetic changes may be valuable, including a process called DNA methylation.
No hay comentarios:
Publicar un comentario